-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MA+NN0Er5W2+i7KoGVb/YTEwVPe6sVw/+qIHOG+0tnXVFacdw5aFf1CcR/PATmJx c+L7nxqV+arBXbrxHaiVEg== 0001178913-09-001606.txt : 20090706 0001178913-09-001606.hdr.sgml : 20090703 20090706164702 ACCESSION NUMBER: 0001178913-09-001606 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20090706 DATE AS OF CHANGE: 20090706 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Barak Avi CENTRAL INDEX KEY: 0001466894 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: C/O BIOCANCELL THERAPEUTICS INC. STREET 2: BECK SCIENCE CENTER, 8 HARTOM STREET CITY: HAR HOTZVIM, JERUSALEM STATE: L3 ZIP: 97775 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIOCANCELL THERAPEUTICS INC. CENTRAL INDEX KEY: 0001451980 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 204630076 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-84912 FILM NUMBER: 09931201 BUSINESS ADDRESS: STREET 1: BECK SCIENCE CENTER STREET 2: 8 HARTOM STREET, HAR HOTZVIM CITY: JERUSALEM STATE: L3 ZIP: 97775 BUSINESS PHONE: 972-2-548-6555 MAIL ADDRESS: STREET 1: BECK SCIENCE CENTER STREET 2: 8 HARTOM STREET, HAR HOTZVIM CITY: JERUSALEM STATE: L3 ZIP: 97775 SC 13G 1 zk96975.htm SC 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
Under the Securities Exchange Act of 1934

BioCancell Therapeutics, Inc.
(Name of Issuer)

Common Stock, par value $0.01 per share
(Title of Class of Securities)

(CUSIP Number)

Avi Barak
Beck Science Center
8 Hartom St.
Jerusalem, Israel 97775

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

Copy to:

Robert Cohen, Esq.
Greenberg Traurig, LLP
200 Park Avenue
New York, New York 10166

June 22, 2009
(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

x Rule 13d-1(c)

o Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 2 of 4 CUSIP No. ______
1 NAME OF REPORTING PERSON

Avi Barak
2 CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP
(a) o
(b) o
3 SEC USE ONLY
 
4 CITIZENSHIP OR PLACE OF ORGANIZATION

Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH 		5 SOLE VOTING POWER
769,033
6 SHARED VOTING POWER
0
7 SOLE DISPOSITIVE POWER
769,033
8 SHARED DISPOSITIVE POWER
0
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

864,708
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

5.52 %
12 TYPE OF REPORTING PERSON

IN

2

Page 3 of 4 CUSIP No. ______

Item 1.

  Item 1(a) Name of issuer: BioCancell Therapeutics, Inc.

  Item 1(b) Address of issuer’s principal executive offices: Beck Science Center, 8 Hartom St, Har Hotzvim, Jerusalem 97775, Israel 972-2-548-6555.

Item 2.

  2(a) Name of person filing: Avi Barak

  2(b) Address or principal business office or, if none, residence: Beck Science Center, 8 Hartom St, Har Hotzvim, Jerusalem 97775, Israel 972-2-548-6555

  2(c) Citizenship: Israel

  2(d) Title of class of securities: Common Stock, par value $0.01 per share

  2(e) CUSIP No.:

Item 3.

  Not applicable.

Item 4. Ownership

  Amount beneficially owned: 864,708 shares

  Percent of class: 5.52%

  Number of shares as to which such person has: 769,033

  Sole power to vote or to direct the vote: 769,033

  Shared power to vote or to direct the vote: 0

  Sole power to dispose or to direct the disposition of: 769,033

  Shared power to dispose or to direct the disposition of: 0

Item 5.

  Not applicable.

Item 6. Ownership of More than 5 Percent on Behalf of Another Person

  Not applicable.

3

Page 4 of 4 CUSIP No. ______

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

  Not applicable.

Item 8. Identification and Classification of Members of the Group

  Not applicable.

Item 9. Notice of Dissolution of Group

  Not applicable.

Item 10. Certifications

        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature.

        After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 6, 2009 /s/ Avi Barak
  Avi Barak

4

 -----END PRIVACY-ENHANCED MESSAGE-----